Nucleix Lands €50K EU Grant to Develop EpiCheck Cancer Screening Tests | GenomeWeb

This story has been updated with additional information from Nucleix.


NEW YORK (GenomeWeb) – Israeli cancer diagnostics firm Nucleix has announced a €50,000 ($56,998) Horizon 2020 grant from the European Commission to support commercial development of lung and colorectal cancer screening products.

The Rehovot-based firm will use the funds to continue developing cancer screening tests based on its EpiCheck platform, which identifies DNA methylation patterns extracted from urine and blood samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.

Apr
11
Sponsored by
Personal Genome Diagnostics

This webinar will provide an overview of genomic alterations that play a role in immunotherapy response.

May
04
Sponsored by
Qiagen

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

May
23
Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants.